tbuckley/cabot-search huggingface dataset:
CA-125 in primary mediastinal B-cell lymphoma with sclerosis.
Authors: C Ravoet, J L Dargent, F Le Moine, W Feremans
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.2.530 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7741868 CA-125 in primary mediastinal B-cell lymphoma with sclerosis. C RavoetxC RavoetSearch for articles by this author , J L DargentxJ L DargentSearch for articles by this author , F Le MoinexF Le MoineSearch for articles by this author , W FeremansxW FeremansSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.2.530 PDF "CA-125 in primary mediastinal B-cell lymphoma with sclerosis.." Journal of Clinical Oncology, 13(2), pp. 530–531© 1995 by American Society of Clinical Oncology
Blood shift during cough in healthy subjects
Authors: Antonella LoMauro, Antonio Pedotti, Peter T. Macklem, Andrea Aliverti
Journal: European Respiratory Journal (2011)

Double Body Plethysmography (DBP), which combines total body plethysmography and opto-electronic Plethysmography, has been recently developed to measure the amount of blood displaced from the thorax to the extremities (Aliverti et al, PLoS One. 2009). By using DBP, we have recently shown that significant blood shifts (BS) occur during expulsive maneuvers and that abdominal pressure controls the outflow of blood from the splanchnic vasculature (Aliverti et al, J Appl Physiol, 2010).  We hypothesized that also during cough a significant amount of blood can be displaced from the trunk to the extremities. We studied 7 healthy subjects (age: 28.6±2.5 yrs) during series of voluntary coughs at four different operating volumes: functional residual capacity (FRC), total lung capacity (TLC) and two intermediate volumes between FRC and TLC (namely, FRC+ and FRC++). BS from the thorax to the extremities were measured by DBP during quiet breathing and during cough at each operating lung volume. The results are shown in figure.  BS during cough resulted significantly higher than during QB (p  These findings might help to better understand the cardiopulmonary interactions during cough and the mechanism by which coughing during asystolic cardiac arrest can maintain consciousness in human subjects.
Antimicrobial peptides cathelicidin (LL-37) ve human β2 defensin levels of pediatric patients with bronchiolitis obliterans
Authors: Ahmet Hakan Gedik, Erkan Cakir, Yasemin Gokdemir, Zeynep Seda Uyan, Abdurrahim Kocyigit, Emel Torun, Bulent Karadag, Refika Ersu, Fazilet Karakoc, Ahmet Hakan
Journal: European Respiratory Journal (2014)

Introduction:  Antimikrobial peptides (AMP) are one of the most important component of innate immune system and have important role in many respiratory disease. No data is available in the literature about the levels of AMP in pediatric patients with bronchiolitis obliterans.  Aim:  To determine cathelicidin and defensin levels and compare between BO patients and control group.  Method:  The patients between 0-16 years-old was admitted between 2012-2013 september and age and gender matched healthy controls were enrolled in the multi-center study. Serum cathelicidin (LL37) ve β2 defensin levels were determined with ELISA method.  Findings  :  Sixty-three BO patients, sixty-seven percent of them were male, enrolled in the study. Median age was 74±58 months. Sixty-five children included to the study as control group and age and gender distribution were not statistically different between the two groups (p>0,05). Cathelicidin and β2 defensin levels were significantly higher in BO group compared with healthy controls (p Conclusion  :  This is the first study about AMP levels of pediatric BO patients. Cathelicidin and β2 defensinlevels were significantly higher in pediatric BO patients. AMP may have important roles in immune systems of pediatric BO patients.
Regulatory T cells (T-Regs) in breast cancer sentinel nodes (SN): FOXP3 expression analysis
Authors: M. A. Thorat, R. Saxena, S. S. Badve
Journal: Journal of Clinical Oncology (2008)

22175 Background: Host immune responses play an important role in breast cancer. Primary breast tumors with predominant Th-1 response have better survival. Tumors with higher proportion of regulatory T cells (T-Regs) inducing Th-1 to Th-2 shift have poorer survival. Transcription factor FOXP3, key regulatory gene for the development of T-Regs, is also a good immunohistochemistry (IHC) marker for identifying T-Regs. It is generally accepted that recruitment of T-Regs in tumors may help cancer cells to evade host immune responses. However, host immune response after cancer cells have escaped primary tumors is not well studied. We studied host immune response in SN using FOXP3 expression. Methods: From our invasive breast cancer database, we randomly selected 68 and 70 cases having SNs with metastasis (SN+) or without metastasis (SN-) respectively. IHC was performed on nodes using FOXP3 antibody 236A/E7 (Abcam). Cortical cells expressing FOXP3 (nuclear expression) were counted in 10 high power fields (hpf). Data were analyzed using SPSS 15.0 software. Results: SN+ and SN- groups were well balanced for all clinico-pathological parameters. Evaluable FOXP3 expression was obtained in 66 SN+ and 69 SN- (3 sections lost). SN+ (mean=139) and SN- groups (mean=132) did not differ in FOXP3 expression (p=0.540). Younger patients (<35 yrs) had higher FOXP3 expression (mean=162) as compared to older patients (mean=133; p=0.250). FOXP3 expression did not differ significantly between 2 groups even after adjusting for age. FOXP3 expression also did not correlate with molecular subtypes. Conclusions: T-Regs recruitment is not altered after regional metastases indicating evasion of local immune mechanisms. This may be one reason why secondary immunological approaches (e.g. Antibodies) rather than primary (e.g. vaccines) are more successful in breast cancer patients with evidence of nodal or systemic metastasis. No significant financial relationships to disclose.
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Authors: V W Rusch, D Niedzwiecki, Y Tao, C Menendez-Botet, A Dnistrian, D Kelsen, L Saltz, M Markman
Journal: Journal of Clinical Oncology (1992)

Intrapleural cisplatin-based chemotherapy has been used in the treatment of patients with malignant pleural mesothelioma and malignant pleural effusions, but the pharmacokinetics of this form of chemotherapy have not been previously evaluated. We performed pharmacokinetic studies on 12 patients who received both intrapleural cisplatin and mitomycin immediately following pleurectomy/decortication for malignant pleural mesothelioma.Simultaneous pleural fluid and plasma samples were collected at 15 and 30 minutes, and at 1, 2, 3, 4, and 24 hours after administration of the intrapleural chemotherapy (cisplatin 100 mg/m2 and mitomycin 8 mg/m2), and after cisplatin (total and free) and mitomycin levels were measured. The mean peak levels, the areas under the concentration-time curve (AUC) and the drug half-lives (t1/2s) in plasma and pleural fluid were compared using the paired t test. Differences were considered significant if P less than or equal to .05.Systemic absorption was rapid, with peak plasma levels being reached within 1 hour of administration of the intrapleural chemotherapy. Peak plasma levels measured after intrapleural chemotherapy approximated those reportedly attained during systemic administration of these drugs at similar doses. However, the mean peak cisplatin and mitomycin levels, and their mean AUCs, were significantly higher in the pleural fluid than in the plasma. There was a three- to fivefold advantage (on a logarithmic scale) for pleural to plasma AUCs for both cisplatin and mitomycin. The mean t1/2s for cisplatin and mitomycin were significantly longer in the plasma than in the pleural fluid.The pharmacokinetics of intrapleural cisplatin-based chemotherapy are analogous to those of intraperitoneal chemotherapy. Our findings show that intrapleural cisplatin-based chemotherapy has a distinct local pharmacologic advantage, but also produces significant and sustained drug plasma levels.
Involving patients in enrolment decisions for acute myocardial infarction trials
Authors: Neal W Dickert, Franklin G Miller
Journal: BMJ (2015)

Seriously ill patients requiring emergency treatment are unlikely to be able to give full informed consent for a clinical trial, but <b>Neal W Dickert</b> and <b>Franklin G Miller </b>argue that this does not mean that they shouldn’t be involved in enrolment decisions at all
Buscopan or Glucagon for Endoscopic Cannulation of Ampulla of Vater?
Authors: B F Hannigan, S Avery, A T R Axon, R P H Thompson
Journal: Journal of the Royal Society of Medicine (1982)

The number of intravenous injections of hyoscine-N-butylbromide (Buscopan) or glucagon required to maintain relaxation of the duodenum during endoscopic retrograde cholangiopancreatography (ERCP) were compared in a double blind trial of 55 patients. There was no significant difference in the number of injections. Serum amylase levels after the use of both relaxants were compared in 50 patients undergoing ERCP. No significant difference in the levels of hyperamylasaemia were found.
Ian Alexander McGregor Joseph McNutt Lawrence Arthur Pike Elizabeth Maria Thompson Emily Katharine Williams
Authors: M. H C Webster, P. MacFarlane, A. McNutt, I. Cox, M. Clarkson, I. M. Thompson, R. Knight
Journal: BMJ (1998)

# Ian Alexander McGregor {#article-title-2}

Former consultant plastic surgeon Canniesburn Hospital ( b Glasgow 1921; q Glasgow 1944 (commendation); ChM, FRCS), d 13 April 1998. He served in the Royal Army Medical Corps in 1945-8 in Egypt, Palestine, and Somaliland. His postgraduate training began with a year in the anatomy department, and a love of anatomical detail remained with him. Director of Canniesburn Hospital from 1980 to 1986, he contributed largely to its eminence as an international centre of excellence for plastic surgical care and training. He received numerous international honours, in 1984-6 was president of the Royal College of Physicians and Surgeons of Glasgow, and in 1979 was president of the British Association of Plastic Surgeons. His book Fundamental Techniques in Plastic Surgery , first published in 1960, is now in its 9th edition—a recent review suggested that a copy should be fixed to the wall of every accident and emergency department in the land. He also contributed to and was a coeditor of several textbooks. Ian was essentially a shy man, but was not a diplomat and indeed the manner in which he laid …
The effects of whole life arsenic exposure via drinking water on airway hyperresponsiveness in C57BL/6 mice
Authors: Kathryn A. Ramsey, Alexander N. Larcombe, Peter D. Sly, Graeme R. Zosky
Journal: European Respiratory Journal (2011)

Background:  Arsenic exposure via drinking water is a significant global environmental health issue. Epidemiological data suggest a relationship between arsenic exposure and the development of obstructive lung disease.   Aims:  We aimed to determine if whole life arsenic exposure via drinking water impairs lung function and results in airway hyperresponsiveness.   Methods:  Pregnant C57BL/6 mice were exposed to drinking water containing 0 (control) or 100μg/L arsenic from gestational day 8 to parturition. After birth, offspring were exposed to arsenic (or control) in breastmilk/drinking water until adulthood (8 weeks of age). At this time lung mechanics and responsiveness to methacholine were assessed using the forced oscillation technique.   Results:  Arsenic exposed mice had significantly higher baseline airway resistance (R aw : arsenic 0.47±0.15 cm H 2 O.s.mL -1 ; control 0.35±0.09 cm H 2 O.s.mL -1 , p = 0.03) and significantly higher maximum response to methacholine (R aw : arsenic 2.08±0.15 cm H 2 O.s.mL -1 ; control 1.25±0.42, p    Conclusions:  We have shown that mice exposed to arsenic throughout life have impaired baseline lung function and airway hyperresponsiveness as adults. These findings support the notion that ingested arsenic is a novel respiratory toxin and may be an important risk factor for the development of obstructive lung disease in arsenic exposed populations.
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity
Authors: Christian A. Fernandez, Colton Smith, Wenjian Yang, Charles G. Mullighan, Chunxu Qu, Eric Larsen, W. Paul Bowman, Chengcheng Liu, Laura B. Ramsey, Tamara Chang, Seth E. Karol, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Stephen P. Hunger, William L. Carroll, Sima Jeha, Ching-Hon Pui, William E. Evans, Meenakshi Devidas, Mary V. Relling
Journal: Blood (2015)
Filmless Images for Radiology Teaching
Authors: Asim Afaq
Journal: Journal of the Royal Society of Medicine (2001)

In his excellent introduction to digital X-ray systems, (August 2001 JRSM, pp. 391-395), Dr Shaw reveals many of the advantages of the picture archive communication system (PACS). An additional area of potential benefit is in the teaching of radiology. This idea has been discussed since PACS was in its infancy1, but it deserves emphasis in view of the limited amount of radiology taught to medical students today. Basic image interpretation is usually taught on the ward, by sporadic and isolated demonstrations of radiological signs. PACS would allow call-up of images from other patients, to emphasize a particular feature, as well as radiological changes on follow-up. Studies on the role of PACS in teaching in the USA have yielded promising results. One report revealed that an electronic final examination for medical students, prepared with images downloaded from PACS or digital teaching collections, was feasible, easy to prepare and cost-effective, and it provided an excellent display of test images2. Additionally, teaching in how to prepare and deliver electronic presentations of radiological cases downloaded from PACS was well appreciated by the students3.

In a hospital equipped with PACS, teaching of radiology can be improved with little additional hardware or software. Use of PACS and PACS-derived teaching files could make a big difference to student confidence and ability in interpretation of radiological images.
Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.
Authors: T. Conroy, F. Desseigne, M. Ychou, M. Ducreux, O. Bouche, R. Guimbaud, Y. Becouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A. Adenis
Journal: Journal of Clinical Oncology (2010)

4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate > 30% (Ychou, ASCO 2007). Because the trial met its planned objectives, it has been pursued as a phase III to compare overall survival (OS). Methods: Chemotherapy-naïve pts aged 18-75 years with histologically/cytologically-confirmed measurable MPA were randomized to receive F (O 85 mg/m2 d1 + I 180 mg/m2 d1 + LV 400 mg/m2 d1 followed by 5FU 400 mg/m2 bolus d1 and 2,400 mg/m2 46h continuous infusion biweekly) or G (1g/m2 IV weekly x7, 1 w rest, then weekly × 3q4w). Eligibility included adequate organ function, performance status (PS) 0-1, no prior chemotherapy or radiotherapy. Pts were stratified by centre, PS, and primary tumor location (head vs. other). The primary endpoint was OS. With a planned sample size of 360 pts, the trial was designed to detect an improvement from 7 to 10 months (m) median survival (HR = 0.70) with 80% power and α = 0.05. Results: 342 pts were enrolled between 01/2005 and 10/2009. Pts were well balanced for baseline characteristics: male 63%; median age 60 years; PS 0 38%. At the planned interim analysis, the Independent Data Monitoring Committee recommended to stop the study. Among 250 treated and monitored pts, median relative dose-intensities of 5FU, I, O and G were 0.81, 0.80, 0.78 and 1.01 respectively. Grade 3/4 toxicities per pts (%) in arms F/G were diarrhea 12.3/1.6, nausea 15.6/6.3, vomiting 17.2/6.3, fatigue 24/14.3, neutropenia 47.9/19.2 and febrile neutropenia 5.7/0. No toxic death occurred. Confirmed response rates (F/G) were 27.6% and 10.9% (p = 0.0008). Median follow-up was 19.5 m. Median PFS was 6.4/3.4 m (p < 0.0001). As of 09/2009, median OS was 10.5/6.9 m (HR = 0.61; 95%CI = 0.46-0.81; p < 0.001). Conclusions: F is the first non containing G therapy that has shown a significantly longer OS, PFS and higher response rate than G alone. The toxicities of this regimen are manageable and F may emerge as a new standard for treatment of MPA in pts with good PS. Final analysis on the total population will be presented. No significant financial relationships to disclose.
Non-alcoholic steatohepatitis (NASH) in patients with breast cancer and association with tamoxifen
Authors: T. Saphner, S. Triest-Robertson
Journal: Journal of Clinical Oncology (2008)

11528 Background: Non-alcoholic steatohepatitis is a form of liver damage that can progress to cirrhosis of the liver. NASH is microscopically identical to steatohepatitis that is noted in alcoholics. The condition is associated with obesity and diabetes. NASH may also be associated with some medications including tamoxifen. Early case reports and small series documented NASH in patients who received tamoxifen. Methods: The St Vincent Hospital Cancer Registry of Green Bay Wisconsin was used to identify breast cancer patients for this retrospective review. Clinic records of patients with breast cancer diagnosed from January 1, 1992 until December 31, 2000 were reviewed. NASH was diagnosed if documented by liver biopsy or if documented by transaminases 2 times the upper range of normal on two occasions and computerized tomography scan or ultrasound documentation of a fatty liver. Results: 1,105 patients with breast cancer were evaluated for NASH. 24 cases of NASH were documented (2.2%). 7 patients had NASH prior to a diagnosis of breast cancer and 17 cases of NASH were discovered after the diagnosis of breast cancer. Patients who developed NASH had a higher mean Body Mass Index (BMI) than those with out NASH (35 vs. 29 kg/m2, p = 0.000). NASH was more common in diabetics than non diabetics (p = 0.001). NASH was more common in patients who received tamoxifen than those who did not. NASH occurred in 16 of 806 patients who took tamoxifen and 1 of 292 patients who did not take tamoxifen (p=0.05). Patients who took tamoxifen were older than those who did not but the frequency of diabetes and obesity were not different between the groups. After discontinuation of tamoxifen, transaminases returned to normal in 14 of 16 patients. Conclusions: NASH was present in 24 of 1,105 patients with breast cancer (2.2%). 7 patients had NASH prior to the diagnosis of breast cancer. 17 patients developed NASH after the diagnosis of breast cancer. NASH was more common in patients who were obese (p = 0.000). NASH was more common in patients who were diabetic (p = 0.001). NASH was more frequent in patients who took tamoxifen (p = 0.05). NASH tended to improve after tamoxifen was stopped. No significant financial relationships to disclose.
Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors
Authors: J. D. Wolchok, V. de Pril, G. Linette, W. Waterfield, T. Gajewski, V. Chiarion-Sileni, R. Ibrahim, K. Chin, A. Hoos, O. Hamid
Journal: Journal of Clinical Oncology (2009)

9036 Background: Ipilimumab is a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen-4. In total, ∼50% of metastatic melanoma pts treated with 10 mg/kg ipilimumab are alive at 1 year (Wolchok et al. CRI-CVC annual meeting 2008. Oral presentation), and identifying prognostic factors may help select pts most likely to benefit from treatment. Factors predictive of poorer prognosis in melanoma include advanced stage of disease (ie, M1c), age 60+, gender (male), elevated baseline lactate dehydrogenase (LDH) levels, and lack of a prior response to therapy. In this pooled analysis, potential prognostic factors in pts with advanced melanoma treated with ipilimumab 10 mg/kg in 2 phase II studies (CA184–008, N=155 and -022, N=72) were explored. Methods: Ipilimumab 10 mg/kg was given every 3 weeks (Q3W) × 4 (induction); eligible pts could continue to receive ipilimumab Q12W starting at week (Wk) 24 (maintenance). Response was based on modified World Health Organization criteria. Each variable was analyzed separately. Results: Disease control rate (complete/partial response [CR/PR] and stable disease) seems not to be associated with age (&lt;65 yrs: 25.2%; ≥65 yrs: 32.9%), gender (male: 22.6%; female: 34.0%), M stage (M0: 33.3%; M1a: 41.0%; M1b: 26.4%; M1c: 23.6%), response to prior systemic therapy (yes: 32.5%; no: 26.7%), prior immunotherapy (yes: 21.6%; no: 35.3%), LDH &gt;upper normal limit (UNL) (yes: 25.9%; no: 29.7%), or LDH &gt;2×UNL (yes: 15.9%; no: 30.6%). Best overall response rate (CR or PR) was not associated with age (&lt;65 yrs: 7.3%; ≥65 yrs: 7.9%), gender (male: 4.0%; female: 11.7%), M stage (M0: 8.3%; M1a: 15.4%; M1b: 5.7%; M1c: 5.7%), response to prior systemic therapy (yes: 12.5%; no: 6.4%), prior immunotherapy (yes: 3.2%; no: 12.7%), LDH &gt;UNL (yes: 8.6%; no: 6.3%), or LDH &gt;2×UNL (yes: 4.5%; no: 8.2%). Overall survival was not associated with age (median OS: &lt;65 yrs: 11.6 mo; ≥65 yrs: 7.59 mo), M stage (median OS: M0: 21.9 mo; M1a: 15.7 mo; M1b: 15.4 mo; M1c: 6.6 mo), or response to prior systemic therapy (median OS: yes: 11.6 mo; no: 10.7 mo). Conclusions: Ipilimumab demonstrates clinical activity independent of negative prognostic factors, and may even benefit those pts with the worst prognosis. [Table: see text]
Plasma and urinary concentrations of inhaled salmeterol in healthy and persons with asthma – Quantifying a doping limit
Authors: Morten Hostrup, Jimmi Elers, John Henninge, Kim Dalhoff, Vibeke Backer
Journal: European Respiratory Journal (2011)

Background:  Salmeterol is a long acting β2agonist that is used in treatment of asthma. β2agonists are on WADA and IOC9s prohibited list, but salmeterol is allowed in therapeutic doses by inhalation. The prohibited list however contains no urinary limit for salmeterol, which gives athletes the opportunity to inhale unlimited doses of salmeterol. Large doses of β2agonists may have ergogenic effects and therefore a quantification of a urine salmeterol limit is necessary.   Purpose:  To find plasma and urinary concentrations of inhaled salmeterol by inhalation in therapeutic dose 100 μg in healthy and persons with asthma. To discuss a urinary concentration limit for inhaled salmeterol on the prohibited list.   Methods:  10 persons with asthma (A) and 10 healthy subjects (C) were enrolled, age 24.6±3.9. The subjects underwent two visits. First visit was a pre-examination with a metacholine provocation and lung function test. On second visit the subjects inhaled 100 μg salmeterol (Serevent © ) as a single dose. Blood samples were acquired at baseline and 0.5, 1, 2, 3, 4 and 6 hours after administration. Urinary samples were collected at baseline and 4, 8 and 12 hours after administration. Plasma and urine samples were analyzed by liquid chromatography mass spectrometry.   Results:  The peak median urinary concentration was found after 4hrs reaching 0.38±0.26 ng mL -1  in A and 0.38±0.22 ng mL -1  in C. Peak median plasma concentration was 0.07±0.03 ng mL -1  for A and 0.06±0.03 ng mL -1  in C. No differences were found between the groups.   Conclusions:  Urine salmeterol peak 4h after administration by inhalation. We propose a salmeterol urine limit of 0.82 ng mL -1  in doping controls.